Silence Therapeutics Plc (SLN):企業の財務・戦略的SWOT分析

◆英語タイトル:Silence Therapeutics Plc (SLN) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH36126FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥88,800見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥133,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Silence Therapeutics plc (Silence Therapeutics), formerly SR Pharma plc is a developer of therapeutics that channels gene silencing to cure life-threatening diseases. The company’s pipeline products include SLN124, SLN500 and SLN360. Its SLN124 is developed for the treatment of cardiovascular disease with high Lp(a); SLN500 for complement-medicated diseases and SLN360 for e-Thalassaemia and myelodysplastic syndrome. Silence Therapeutics also provides RNA interface that include short interfering RNA (siRNA) and messenger RNAs (mRNA). The company collaborates with pharmaceutical, biotechnology companies and academic research institutions. It operates in Germany and the UK. Silence Therapeutics is headquartered in London, the UK.

Silence Therapeutics Plc Key Recent Developments

Mar 30,2021: Silence Therapeutics Reports Full-year 2020 Results
Feb 26,2021: Silence Therapeutics and Mallinckrodt initiate work on third target as part of ongoing RNAi research collaboration for complement-mediated diseases
Jan 06,2021: Silence Therapeutics appoints Michael H. Davidson, MD, to Board of Directors
Jan 06,2021: Silence Therapeutics appoints Craig Tooman as Chief Financial Officer
Nov 02,2020: Silence Therapeutics appoints Dr. Marie Wikstrom

This comprehensive SWOT profile of Silence Therapeutics Plc provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Silence Therapeutics Plc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Silence Therapeutics Plc – Key Information
Silence Therapeutics Plc – Overview
Silence Therapeutics Plc – Key Employees
Silence Therapeutics Plc – Key Employee Biographies
Silence Therapeutics Plc – Key Operational Heads
Silence Therapeutics Plc – Major Products and Services
Silence Therapeutics Plc – History
Silence Therapeutics Plc – Company Statement
Silence Therapeutics Plc – Locations And Subsidiaries
Silence Therapeutics Plc
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Silence Therapeutics Plc – Business Description
Silence Therapeutics Plc – Corporate Strategy
Silence Therapeutics Plc – SWOT Analysis
SWOT Analysis – Overview
Silence Therapeutics Plc – Strengths
Silence Therapeutics Plc – Weaknesses
Silence Therapeutics Plc – Opportunities
Silence Therapeutics Plc – Threats
Silence Therapeutics Plc – Key Competitors

Section 3 – Company Financial Performance Charts

Silence Therapeutics Plc – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Silence Therapeutics Plc, Key Information
Silence Therapeutics Plc, Key Ratios
Silence Therapeutics Plc, Share Data
Silence Therapeutics Plc, Major Products and Services
Silence Therapeutics Plc, History
Silence Therapeutics Plc, Key Employees
Silence Therapeutics Plc, Key Employee Biographies
Silence Therapeutics Plc, Key Operational Heads
Silence Therapeutics Plc, Other Locations
Silence Therapeutics Plc, Subsidiaries
Silence Therapeutics Plc, Key Competitors
Silence Therapeutics Plc, SWOT Analysis
Silence Therapeutics Plc, Ratios based on current share price
Silence Therapeutics Plc, Annual Ratios
Silence Therapeutics Plc, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Silence Therapeutics Plc (SLN):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • EndoGastric Solutions Inc-製薬・医療分野:企業M&A・提携分析
    Summary EndoGastric Solutions Inc (EGS), formerly EsophyX, Inc. is a medical equipment company that manufactures and markets gastroenterology and surgical products. The company’s products include esophy-x device and serosa-fuse fasteners. Its esophy-x device is used in reconstructing the gastroesoph …
  • TUV Rheinland AG:企業の戦略的SWOT分析
    TUV Rheinland AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Dayton Superior Corp:企業の戦略的SWOT分析
    Dayton Superior Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Nevada Gold & Casinos, Inc.:企業の戦略・SWOT・財務分析
    Nevada Gold & Casinos, Inc. - Strategy, SWOT and Corporate Finance Report Summary Nevada Gold & Casinos, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Drax Group Plc (DRX)-エネルギー分野:企業M&A・提携分析
    Summary Drax Group plc (Drax) is a biomass-fuelled electricity generator, which generates electricity from coal and biomass. It operates across three principal areas of activity, electricity generation; electricity sales to business customers; and compressed wood pellet production. The company opera …
  • Rush Enterprises, Inc. (RUSHA):企業の財務・戦略的SWOT分析
    Rush Enterprises, Inc. (RUSHA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Assicurazioni Generali SpA:企業の戦略・SWOT・財務情報
    Assicurazioni Generali SpA - Strategy, SWOT and Corporate Finance Report Summary Assicurazioni Generali SpA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Becle S.A.B. de C.V. (CUERVO):企業の財務・戦略的SWOT分析
    Becle S.A.B. de C.V. (CUERVO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Oryx Petroleum Corp Ltd (OXC):石油・ガス:M&Aディール及び事業提携情報
    Summary Oryx Petroleum Corp Ltd (Oryx Petroleum), a subsidiary of The Addax and Oryx Group Ltd, is an upstream company that explores oil and gas. The company explores, develops and produces natural resources. It holds interests in petroleum license areas in Africa and the Middle East. Oryx Petroleum …
  • Permian Basin Royalty Trust Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Permian Basin Royalty Trust Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Permian Basin Royalty Trust (Permian Basin Royalty) is an oil and gas company that owns overriding royalty rights in mineral properties in the US. The company provides oil and gas product …
  • curasan AG (CUR):企業の財務・戦略的SWOT分析
    curasan AG (CUR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Glycotope GmbH-製薬・医療分野:企業M&A・提携分析
    Summary Glycotope GmbH (Glycotope) is a biopharmaceutical company that develops immuno-oncology products for the treatment of various types of cancer. The company’s expression platform offers proprietary technologies such as Glycobody (GET) and GlycoExpress(GEX) that allows the glycosylation of anti …
  • J.M. Huber Corp:企業の戦略的SWOT分析
    J.M. Huber Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Oracle Energy Corp (OEC):石油・ガス:M&Aディール及び事業提携情報
    Summary Oracle Energy Corp (Oracle Energy) is an oil and gas company that operates development and redevelopment oil and natural gas projects. The company offers critical assessment and mitigation of risk in oil and gas exploration. It owns and operates oil and gas projects in Portugal's southern Lu …
  • Chiesi USA Inc-製薬・医療分野:企業M&A・提携分析
    Summary Chiesi USA Inc (Chiesi USA), a specialty pharmaceutical company, is a wholly-owned subsidiary of Chiesi Farmaceutici S.p.A. The company researches, develops, produces and commercializes innovative products in the areas such as cardiovascular, respiratory, neonatology, rare disease and specia …
  • Trillium Therapeutics Inc (TRIL):製薬・医療:M&Aディール及び事業提携情報
    Summary Trillium Therapeutics Inc (Trillium), formerly Neurogenesis Biotech Corp, is a clinical stage immuno-oncology company, which develops novel therapies for the treatment of cancer. The company’s lead program, TTI-621, a SIRPaFc fusion protein is being developed for hematological malignancies. …
  • Aminex PLC (AEX):企業の財務・戦略的SWOT分析
    Summary Aminex plc (Aminex) is an oil and gas company that explores, develops and produces oil and gas reserves in Africa. The company provides assets such as Valeni field and Viktorovka field in Moldova; West Esh el Mellaha-2 in Egypt; and Kiliwani North development, Nyuni exploration and Ruvuma ex …
  • Banco do Brasil SA:企業のM&A・事業提携・投資動向
    Banco do Brasil SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Banco do Brasil SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • Narada Power Source Co Ltd (300068):企業の財務・戦略的SWOT分析
    Summary Narada Power Source Co Ltd (Narada Power) is a battery manufacturer and distributor that markets and supplies stored energy solutions. The company's products include eos series batteries, acme series, acmeG series, GP series, TTG series, TT series, eosG series, GPG series, MP series, HRL ser …
  • eBay Korea Co., Ltd.:企業の戦略的SWOT分析
    eBay Korea Co., Ltd. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆